MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session

Reuters

06-21

<a href="https://laohu8.com/S/MTVA">MetaVia Inc</a>. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session

Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes® online.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15094) on June 21, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2545486451"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545486451\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545486451?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-21 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545486451","market":"us","top_or_hot":-1,"title":"MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes® online.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15094) on June 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-21 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MTVA\">MetaVia Inc</a>. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes® online.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15094) on June 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MTVA","symbol_name":"MetaVia Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250621:nNDL9HFWGp:1","article_id":"2545486451","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545486451","pubTimestamp":1750510819,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session. Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis . The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes online.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MTVA":"MetaVia Inc","BK4139":"生物科技"},"translate_title":"MetaVia Inc.在ADA科学会议上宣布DA-1241与Efruxifermin联合治疗MASH的有希望的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MTVA":0.9},"content_text":"MetaVia Inc. Announces Promising Pre-Clinical Data on DA-1241 with Efruxifermin Combination for MASH Treatment at ADA's Scientific Session\n    \n\n        Metavia Inc. announced new pre-clinical data on their novel drug, DA-1241, at the American Diabetes Association's 85th Scientific Sessions in Chicago, Illinois. The study highlights the additive hepatoprotective effects of DA-1241, a G-Protein-Coupled Receptor 119 agonist, when combined with Efruxifermin, a fibroblast growth factor 21 analogue, in a mouse model of metabolic dysfunction-associated steatohepatitis (MASH). The data, presented on June 22, 2025, by Yuna Chae, Lead Research Scientist at Dong-A ST Research Center, demonstrated synergistic benefits in reducing liver fat, inflammation, and fibrosis. These findings build upon previous Phase 2a clinical trial results and will be accessible on MetaVia's website and the journal Diabetes® online.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15094) on June 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}